THE ROLE OF TIOTROPIUM AND OLODATEROL COMBINATION IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Inhaled bronchodilators are themain treatment of chronic obstructive pulmonary disease and are recommended by GlobalObstructive Lund Disease Initiative (GOLD). Long acting anti –muscarins (LAMA) and long acting β2 agonists (LABA) are bothmore effective than regular short – acting drugs. Complementary pharmacological profiles of tiotropium and olodaterol and data from studies of double therapy showed that these medicinal products could be ideal partners. Combination therapy of LAMA and LABA increases therapeutic benefit. Based on this data, a program TOviTO, consisting of 10 third phase clinical trials, was initiated,which comprehensively investigated the benefit of treatmentwith fixed dose combination of tiotropium and olodetarol in single inhalator. The combination of tiotropium and olodaterol 5/5 µg significantly increased forced expiratory volume in first second (FEV1) area under the curve from 0 to 3 hours (FEV1 AUC0–3 h), trough FEV1 health status, tolerance of physical activy, breathlesness and improved the quality of life, comparing with mono – components and placebo.